US-based pharmaceutical firm Horizon Pharma announced Wednesday it will acquire Ireland-based competitor Vidara, a $660 million reverse merger that will allow Horizon to take advantage of low taxes overseas.
Reports say Horizon is set to relocate its headquarters to Ireland through the buyout, which will result in a company known as Horizon Pharma PLC, with 74 percent of the new company being owned by Horizon.
According to reports, Horizon is only the latest pharmaceutical giant to utilize mergers to nab lower taxes in Ireland. Perrigo acquired Ireland-based Elan in a $8.6 billion deal, while Canada’s Paladin merged with Ireland’s Endo Health Solutions.
Full Content: Fox Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI